Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab envedotin (DP303c) in HER2-positive Advanced Solid Tumors
NCT04146610Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DP303c in solid tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Maximal Tolerance Dose at 21 days. Status: unknown.
02
Drugs
DP303c
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04146610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146610.